Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,087.00-1.11%ETH$2,466.81-0.04%GOLD$4,388.60-0.42%OIL$99.17-3.23%
Smart Investors Daily
EV

NYSE · EVM

Eaton Vance California Municipal Bond Fund

Financial Services · Asset Management - Bonds

$9.61

Up+$0.15 (+1.56%)

Updated Sep 11, 2026, 10:27 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
237.05M
P/E ratio
-104.32
Dividend yield
4.34%
52-week range
— – —
Volume
364.39K
Avg. volume
69.03K

Price performance

EVM price history

1M range · 0 trading sessions · Daily adjusted prices

EVM does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest EVM news

The latest Smart Investors Daily articles mentioning EVM.

Stock researchCompany · Overview

EVM research

Overview

Company profile and research snapshot.

Company profile

Eaton Vance California Municipal Bond Fund is a close-ended fixed income mutual fund launched and managed by Eaton Vance Management. The fund invests in the fixed income market of United States. It invests primarily in high grade municipal obligations comprising of various industries, such as general obligations, hospital, electric utilities, transportation, water and sewer, public education, and private education. The fund was formerly known as Eaton Vance Insured California Municipal Bond Fund. Eaton Vance California Municipal Bond Fund was formed in 2002 and is domiciled in United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

businesswire.com · Nov 26, 2025

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM401 Series of molecules being developed as potential treatments for mental health disorders.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By